Evaluation on efficacy and safety of gemcitabine combined with platinum-based chemotherapy for platinum-resistant recurrent ovarian carcinoma

Abstract

Objective To investigate the efficacy and safety of gemcitabine (GEM) combined with oxaliplatin (OX) (GEMOX) in treatment of patients with platinum-resistant recurrent ovarian carcinoma. Methods A total of 32 cases of platinum-resistant recurrent ovarian carcinoma patients who were hospitalized in West China Second University Hospital, Sichuan University from January 2013 to January 2017, were chosen as research subjects. The GEMOX regimen of GEM at the dose of 1 000 mg/(m2·d) was given on day 1 and day 8 by intravenously guttae every 21 days a treatment cycle, and combined OX at the dose of 100 mg/(m2·d) was delivered after GEM infusion on day 1 in the cycle, and the total treatment cycles were 2-6. The therapeutic effect, survival, progression and adverse reactions of 32 patients were analyzed statistically. This study was in line with World Medical Association Declaration of Helsinki revised in 2013. Results ①According to response evaluation criteria in solid tumors (RECIST), after GEMOX chemotherapy, none of the ovarian carcinoma patients in this study had achieved complete remission (CR), while rates of partial remission (PR), stable disease (SD) and progressive disease (PD) were 21.9%(7/32), 28.1%(9/32) and 50.0%(16/32), respectively. The total response rate of platinum-resistant recurrent ovarian carcinoma to GEMOX was 21.9%(7/32), and the clinical objective response rate was 50%(16/32). ②Among the ovarian carcinoma patients in this study, the median overall survival (OS) time was 10.5 months (95%CI: 8.4-12.6 months), median progression free survival (PFS) time was 6.3 months (95%CI: 4.6-7.9 months), one-year OS rate was 34.4%, and one-year PFS rate was 12.5%. ③The hematological adverse reactions of 32 ovarian carcinoma patients showed that 12.5%(4/32) patients had grade 3 neutropenia, 6.3%(2/32) patients had grade 3 leukopenia, and 3.1%(1/32) patients had grade 4 anemia. The non-hematological adverse reactions showed that 3.1%(1/32) patients had grade 3 nausea and (or) vomiting, and hepatotoxicity. Grade 1-2 fatigue was the most common non-hematological adverse reaction among 32 ovarian carcinama patients in this Study, with a total incidence of 65.6%(21/32). Conclusions The GEMOX is a regimen with a beneficial therapeutic efficacy and tolerable adverse reactions in platinum-resistant recurrent ovarian carcinoma patients. Key words: Gemcitabine; Drug resistance; Recurrence; Ovarian neoplasms; Oxaliplatin; Drug therapy; Female